Trial · NCT05640648
Human-centered Design and Communities of Practice to Improve Home-based Tuberculosis Contact Investigation in Uganda
NCT05640648, Not applicable, Completed, Yale University; results first posted 2025-03-30
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Human-centered Design and Communities of Practice to Improve Home-based Tuberculosis Contact Investigation in Uganda. Trials, record NCT05640648. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05640648
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Human-centered Design and Communities of Practice to Improve Home-based Tuberculosis Contact Investigation in Uganda
- NCT number
- NCT05640648
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 10,477 participants, actual
- Lead sponsor
- Yale University
- Conditions
- Tuberculosis, Tuberculosis, Pulmonary
- Interventions
- User-Centered Implementation Strategy, Standard Implementation Strategy
- First posted
- 2022-12-07
- Last updated
- 2025-03-30
- Results first posted
- 2025-03-30
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Completion of TB Evaluation | 60 days | The percentage of participants (close contacts) who are experiencing TB symptoms who complete TB evaluation within 60 days of the TB patient's treatment initiation date |
| Secondary | TB Yield (Diagnosis and Treatment Initiation) | 60 days | The difference between study periods in percentage of contacts diagnosed with active TB and initiated on treatment within 60 days of the TB patient's treatment initiation |
| Secondary | Initiation of TB Preventative Therapy | 60 days | The difference between study periods in percentage of contacts initiating TB preventative therapy (TPT) within 60 days of the TB patient's treatment initiation |
| Secondary | Number of Contacts Diagnosed With Active TB | 60 days | The difference between study periods in counts of the number of contacts diagnosed with active TB |
| Secondary | Number of Contacts Initiating TB Preventative Therapy | 60 days | The difference between study periods in counts of the number of contacts initiating TPT |
| Secondary | TB Yield (All Contacts) | 60 days | The difference between study periods in percentage of all TB cases among contacts |
Source ClinicalTrials.gov
Outcomes6
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Completion of TB Evaluation | 60 days | Only those who screened positive for symptoms of TB are included in this analysis | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | TB Yield (Diagnosis and Treatment Initiation) | 60 days | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Initiation of TB Preventative Therapy | 60 days | Only those eligible for TPT are included in this analysis. Those that have been newly diagnosed with TB, regardless of treatment status, are not eligible for TPT and are therefore excluded from this analysis | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Contacts Diagnosed With Active TB | 60 days | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number of Contacts Initiating TB Preventative Therapy | 60 days | This outcome is only for those eligible to initiate TPT. Those who have been newly diagnosed, regardless of treatment status, are not eligible for TPT and are therefore excluded from this outcome. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | TB Yield (All Contacts) | 60 days | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Completion of TB Evaluation | Standard Implementation Strategy Period | 266 | Participants | ||
| Completion of TB Evaluation | Enhanced Contact Investigation Intervention Period | 1144 | Participants | ||
| TB Yield (Diagnosis and Treatment Initiation) | Standard Implementation Strategy Period | 36 | Participants | ||
| TB Yield (Diagnosis and Treatment Initiation) | Enhanced Contact Investigation Intervention Period | 187 | Participants | ||
| Initiation of TB Preventative Therapy | Standard Implementation Strategy Period | 122 | Participants | ||
| Initiation of TB Preventative Therapy | Enhanced Contact Investigation Intervention Period | 264 | Participants | ||
| Number of Contacts Diagnosed With Active TB | Standard Implementation Strategy Period | 45 | Participants | ||
| Number of Contacts Diagnosed With Active TB | Enhanced Contact Investigation Intervention Period | 201 | Participants | ||
| Number of Contacts Initiating TB Preventative Therapy | Standard Implementation Strategy Period | 122 | Participants | ||
| Number of Contacts Initiating TB Preventative Therapy | Enhanced Contact Investigation Intervention Period | 264 | Participants |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 results by groupParticipant flow480
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Period 1 (Weeks 1-8) | STARTED | Standard Contact Investigation [Control]: Sequence 1 [2 Health Facilities] | 85 | 1 |
| Period 1 (Weeks 1-8) | STARTED | User-centered Contact Investigation [Intervention]: Sequence 1 [2 Health Facilities] | 0 | 0 |
| Period 1 (Weeks 1-8) | STARTED | Standard Contact Investigation [Control]: Sequence 2 [2 Health Facilities] | 297 | 1 |
| Period 1 (Weeks 1-8) | STARTED | User-centered Contact Investigation [Intervention]: Sequence 2 [2 Health Facilities] | 0 | 0 |
| Period 1 (Weeks 1-8) | STARTED | Standard Contact Investigation [Control]: Sequence 3 [2 Health Facilities] | 111 | 1 |
| Period 1 (Weeks 1-8) | STARTED | User-centered Contact Investigation [Intervention]: Sequence 3 [2 Health Facilities] | 0 | 0 |
| Period 1 (Weeks 1-8) | STARTED | Standard Contact Investigation [Control]: Sequence 4 [2 Health Facilities] | 134 | 1 |
| Period 1 (Weeks 1-8) | STARTED | User-centered Contact Investigation [Intervention]: Sequence 4 [2 Health Facilities] | 0 | 0 |
| Period 1 (Weeks 1-8) | STARTED | Standard Contact Investigation [Control]: Sequence 5 [2 Health Facilities] | 110 | 1 |
| Period 1 (Weeks 1-8) | STARTED | User-centered Contact Investigation [Intervention]: Sequence 5 [2 Health Facilities] | 0 | 0 |
1 to 10 of 480Source ClinicalTrials.gov
See all 480 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals36
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Standard Contact Investigation [Control]: Sequence 1 [2 Health Facilities] | 0 | 0 |
| Total, all-cause mortality | User-centered Contact Investigation [Intervention]: Sequence 1 [2 Health Facilities] | 0 | 0 |
| Total, all-cause mortality | Standard Contact Investigation [Control]: Sequence 2 [2 Health Facilities] | 0 | 0 |
| Total, all-cause mortality | User-centered Contact Investigation [Intervention]: Sequence 2 [2 Health Facilities] | 0 | 0 |
| Total, all-cause mortality | Standard Contact Investigation [Control]: Sequence 3 [2 Health Facilities] | 0 | 0 |
| Total, all-cause mortality | User-centered Contact Investigation [Intervention]: Sequence 3 [2 Health Facilities] | 0 | 0 |
| Total, all-cause mortality | Standard Contact Investigation [Control]: Sequence 4 [2 Health Facilities] | 0 | 0 |
| Total, all-cause mortality | User-centered Contact Investigation [Intervention]: Sequence 4 [2 Health Facilities] | 0 | 0 |
| Total, all-cause mortality | Standard Contact Investigation [Control]: Sequence 5 [2 Health Facilities] | 0 | 0 |
| Total, all-cause mortality | User-centered Contact Investigation [Intervention]: Sequence 5 [2 Health Facilities] | 0 | 0 |
1 to 10 of 36Source ClinicalTrials.gov
See all 36 adverse event totalsPapers2
The papers the trial lists on ClinicalTrials.gov.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01AI104824 | Human-centered Design and Communities of Practice to Improve Delivery of Home-based TB Contact Investigation in Uganda | DAVIS, JOHN LUCIAN | YALE UNIVERSITY | NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES | 2013 to 2023 |
Source NIH RePORTER
Trial comparisons6
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Standard Implementation Strategy Period vs Enhanced Contact Investigation Intervention Period: TB Yield (Diagnosis and Treatment Initiation) | Trial comparisons |
| Standard Implementation Strategy Period vs Enhanced Contact Investigation Intervention Period: TB Yield (All Contacts) | Trial comparisons |
| Standard Implementation Strategy Period vs Enhanced Contact Investigation Intervention Period: Completion of TB Evaluation | Trial comparisons |
| Standard Implementation Strategy Period vs Enhanced Contact Investigation Intervention Period: Number of Contacts Initiating TB Preventative Therapy | Trial comparisons |
| Standard Implementation Strategy Period vs Enhanced Contact Investigation Intervention Period: Initiation of TB Preventative Therapy | Trial comparisons |
| Standard Implementation Strategy Period vs Enhanced Contact Investigation Intervention Period: Number of Contacts Diagnosed With Active TB | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05640648
GET https://conductscience.org/api/trials/v1/NCT05640648/flow?page=2